[G25-19] Dalbavancin (acute bacterial skin and skin structure infections, from birth < 3 months) – Assessment in accordance with §35a (1c) Social Code Book V
Last updated 26.08.2025
Project no.:
G25-19
Commission:
Commission awarded on 27.05.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission work started
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Note:
In accordance with §35a (1) Sentence 11 Social Code Book (SGB) V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. On behalf of the Federal Joint Committee (G-BA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier.
| Project no. | Title | Status |
|---|---|---|
| G23-19 | Dalbavancin (acute bacterial skin and skin structure infections, = 3 months) – Assessment according to §35a (para. 1c) Social Code Book V | Commission completed |